Making way for suppressing the FGF19/FGFR4 axis in cancer

Nestor Prieto-Dominguez, Austin Y. Shull, Yong Teng

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

Original languageEnglish (US)
Pages (from-to)2457-2470
Number of pages14
JournalFuture Medicinal Chemistry
Volume10
Issue number20
DOIs
StatePublished - Oct 1 2018

Fingerprint

Bile Acids and Salts
Homeostasis
Neoplasm Metastasis
Ligands
Glucose
Liver
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • FGF19
  • FGFR4
  • anticancer
  • inhibitors
  • oncogenic role
  • signaling transduction
  • treatment regimens

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Making way for suppressing the FGF19/FGFR4 axis in cancer. / Prieto-Dominguez, Nestor; Shull, Austin Y.; Teng, Yong.

In: Future Medicinal Chemistry, Vol. 10, No. 20, 01.10.2018, p. 2457-2470.

Research output: Contribution to journalReview article

Prieto-Dominguez, Nestor ; Shull, Austin Y. ; Teng, Yong. / Making way for suppressing the FGF19/FGFR4 axis in cancer. In: Future Medicinal Chemistry. 2018 ; Vol. 10, No. 20. pp. 2457-2470.
@article{a0241ce6ce684497a58143fece60b9ed,
title = "Making way for suppressing the FGF19/FGFR4 axis in cancer",
abstract = "FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.",
keywords = "FGF19, FGFR4, anticancer, inhibitors, oncogenic role, signaling transduction, treatment regimens",
author = "Nestor Prieto-Dominguez and Shull, {Austin Y.} and Yong Teng",
year = "2018",
month = "10",
day = "1",
doi = "10.4155/fmc-2018-0099",
language = "English (US)",
volume = "10",
pages = "2457--2470",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "20",

}

TY - JOUR

T1 - Making way for suppressing the FGF19/FGFR4 axis in cancer

AU - Prieto-Dominguez, Nestor

AU - Shull, Austin Y.

AU - Teng, Yong

PY - 2018/10/1

Y1 - 2018/10/1

N2 - FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

AB - FGF19 is a noncanonical FGF ligand that can control a broad spectrum of physiological responses, which include bile acid homeostasis, liver metabolism and glucose uptake. Many of these responses are mediated by FGF19 binding to its FGFR4/β-klotho receptor complex and controlling activation of an array of intracellular signaling events. Overactivation of the FGF19/FGFR4 axis has been implicated in tumorigenic formation, progression and metastasis, and inhibitors of this axis have recently been developed for single agent use or in combination with other anticancer drugs. Considering the critical role of this receptor complex in cancer, this review focuses on recent developments and applications of FGF19/FGFR4-targeted therapeutics.

KW - FGF19

KW - FGFR4

KW - anticancer

KW - inhibitors

KW - oncogenic role

KW - signaling transduction

KW - treatment regimens

UR - http://www.scopus.com/inward/record.url?scp=85055602473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055602473&partnerID=8YFLogxK

U2 - 10.4155/fmc-2018-0099

DO - 10.4155/fmc-2018-0099

M3 - Review article

VL - 10

SP - 2457

EP - 2470

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 20

ER -